Single Ascending Dose Study of AMG 570 in Healthy Subjects: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Single Ascending Dose Study of AMG 570 in Healthy Subjects (NCT02618967), a randomized phase 1 study. The primary outcome is Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs).

2. Clinical Question

3. Trial Design

This was a randomized, double-blind, placebo-controlled, first-in-human study of a single subcutaneous dose of AMG 570 in healthy subjects. The registry lists the masking as quadruple. It also classifies the study model as single-group, while listing seven AMG 570 dose groups and a placebo group. Those recorded design details are not reconciled in the registry record, so the precise allocation structure should not be inferred from the model label alone.

The registry reports an enrollment of 56. The AMG 570 groups are listed at 7 mg, 21 mg, 70 mg, 140 mg, 210 mg, 420 mg, and 700 mg; the placebo group received matching placebo. The listed safety denominators are 6 participants in each AMG 570 group and 14 in the placebo group. These group counts describe the safety results, and are not a basis for inferring unreported allocation procedures.

The study is designated Phase 1 and is marked completed. Its recorded start date is 2016-03-28, and its primary completion date is 2018-09-06. The stated purpose was to obtain initial information about safety and tolerability, pharmacokinetics, and pharmacodynamics after a single dose. The registry also lists secondary measures concerning drug concentration, antibody results, receptor occupancy, and B-cell measures. The detailed protocol, dose-escalation procedure, and statistical design rationale are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 8 groups are shown.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety analysis set: all participants who received AMG 570 or placebo.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The safety analysis set: all participants who received AMG 570 or the placebo.

Only the first 6 of 9 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs), measured over Day 1 to Day 105.

The primary endpoint is the number of participants who experienced one or more treatment-emergent adverse events, with the assessment timeframe listed as Day 1 to Day 105. The record defines these events by timing: onset must occur after study treatment. This endpoint summarizes how many participants had at least one such event, rather than counting every event as a separate participant-level outcome.

For an early first-in-human study, a participant-level adverse-event measure can describe the observed safety experience after exposure to the study treatment. The record says events were graded using Common Terminology Criteria for Adverse Events version 4.0, and provides definitions for grades 2, 3, and 4. It also defines serious adverse events according to criteria such as hospitalization, life-threatening events, disability, or other medically important events. These definitions distinguish event severity and seriousness; they are not interchangeable classifications.

The posted record does not give an analysis of the primary endpoint, such as a modeled estimate, confidence interval, or statistical comparison by dose. Its adverse-event listings report serious and other affected-participant counts, but the registry record does not explicitly connect those summaries to a complete endpoint analysis. The endpoint therefore describes the intended primary safety question, while the numerical summaries should be interpreted according to the categories actually reported.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The record describes a randomized, double-blind, placebo-controlled study, but does not report the randomization method, allocation concealment details, or the procedures used to maintain masking. Randomization is generally intended to reduce systematic differences between assigned groups, while masking is generally intended to limit the influence of treatment knowledge on participant behavior and outcome assessment. These are general methodological purposes, not claims about implementation details beyond the labels in the registry.

The record labels the model as single-group while also listing multiple dose groups and a placebo group. This is an inconsistency in the recorded design descriptions that cannot be resolved from the registry information. It is therefore safest to describe the arms as they are listed, without inferring whether the study used sequential cohorts, parallel allocation within cohorts, or another structure.

What does a participant count describe?

The primary endpoint is a participant count: the number of participants who experienced one or more treatment-emergent adverse events. A participant with several events would still count once for this endpoint if the outcome is defined as having at least one event. Event counts and participant counts answer different questions. The registry's adverse-event summary distinguishes participants affected by serious events from those affected by other events, but does not provide a full analysis of the primary endpoint.

In general, counts can be displayed descriptively by group, but a comparison requires a defined estimand and an analysis method. An estimand specifies the outcome being compared, the population, the treatment conditions, and how events such as discontinuation are handled. The registry record does not report a formal estimand, a treatment-effect measure, a model, or a hypothesis test for the primary endpoint. The record lists no analyses.

Why are small group counts uncertain?

In general, estimates based on small groups can vary substantially with the experience of individual participants. A confidence interval expresses the range of values compatible with the data under a specified statistical model and its assumptions. The registry record does not report confidence intervals for the primary endpoint or the listed adverse-event summaries. Without such uncertainty estimates, the counts should be read as observed descriptions rather than precise estimates of event frequency in a wider population.

There is also no basis for treating a lack of events in a group as proof of no risk. A small observed count may be compatible with a range of underlying event rates. Likewise, differences in observed counts across groups can reflect chance variation, and the registry does not provide an inferential analysis that would quantify such uncertainty.

What does the phase and dose structure imply?

As a general matter, an early-phase, first-in-human study can characterize initial safety and exposure patterns. The listed dose groups and single-dose administration are consistent with a study focused on initial observations across dose levels, but the registry does not report the dose-escalation rules, cohort review process, stopping criteria, or any planned interim review. Those details should not be inferred from the group list.

The registry does not report a sample-size justification or a statistical power calculation for the study's primary endpoint. Any sample-size planning illustration based on an observed effect is not the study's original design rationale and should not be interpreted as observed power. For a safety study with small groups, a planning illustration cannot replace the missing protocol rationale or establish that the design was powered to detect a particular safety difference.

How should the outcome definitions be read?

The record defines treatment-emergent adverse events by onset after administration of study treatment and gives CTCAE version 4.0 grading information. It separately defines serious adverse events using regulatory-style seriousness criteria, including death, life-threatening events, hospitalization, persistent disability, congenital anomaly, and other medically important events. Severity grading and seriousness are different dimensions: an event may be serious because of its consequences or required care, while severity grading describes its clinical intensity under the stated grading system.

The adverse-event summary provides counts of participants affected, not event narratives or time-to-event analyses. It does not report exposure-adjusted rates or detailed event duration and resolution. The posted registry record therefore supports a limited descriptive reading, not a full comparative safety analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary safety endpoint and secondary outcomes covering pharmacokinetic measures, antibody results, receptor occupancy, and B-cell measures. It does not report a statistical analysis plan or explain how multiple secondary outcomes, dose groups, or comparisons were handled. Multiplicity refers generally to the increased chance of false-positive findings when many statistical tests are conducted; whether and how that issue was addressed is not reported in the registry record.

The record lists 13 outcome measures and 0 analyses. It does not report outcome-level estimates, confidence intervals, p-values, or a hierarchy of hypotheses in the information recorded. The absence of reported analyses means that statistical significance, precision, and between-group differences cannot be assessed from the posted record. No adjustment method, if any, should be assumed.

The record identifies a safety analysis set consisting of all participants who received AMG 570 or placebo. It does not report an intention-to-treat population, a per-protocol population, or rules for handling participants who withdrew, missed assessments, or had incomplete data. Missing-data handling and the extent of missingness are not reported in the registry record.

The planned primary timeframe is Day 1 to Day 105, but the record does not explain whether participants with incomplete follow-up were included, excluded, or otherwise handled in the endpoint summary. It also does not report protocol deviations or the number of participants assessed at each time point. These omissions limit interpretation of whether the posted counts represent complete follow-up for every participant.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: injury (16.7%).

Serious adverse events were recorded for 1 of 6 participants in the AMG 570 7 mg group. The recorded count was 0 of 6 in each of the other AMG 570 groups and 0 of 14 with placebo. The term summary lists Injury at 16.7%. The registry does not provide a fuller event narrative or a statistical comparison for these serious-event counts.

The separate other-adverse-event counts were 6 of 6 at 7 mg, 5 of 6 at 21 mg, 4 of 6 at 70 mg, 4 of 6 at 140 mg, 2 of 6 at 210 mg, 3 of 6 at 420 mg, 4 of 6 at 700 mg, and 9 of 14 with placebo. These are counts of participants affected, not counts of all event episodes. The record lists 0 deaths in every group.

Seriousness is not the same as severity: the record defines seriousness using consequences such as hospitalization or life-threatening status, while CTCAE grading describes event severity. These descriptive figures do not establish causality or a treatment effect. Small groups and the absence of reported uncertainty estimates mean the counts should not be read as precise comparisons.

12. What the Result Does, and Does Not, Mean

The registry record documents a randomized, masked, placebo-controlled, first-in-human study of single subcutaneous doses of AMG 570 in healthy subjects. It reports participant counts for serious and other adverse events, and lists no deaths. These observations describe what was recorded in the study groups; they do not, by themselves, establish that AMG 570 caused an event or that event frequency differs from placebo.

The study's primary endpoint concerns participants with one or more treatment-emergent adverse events from Day 1 to Day 105. The registry does not post an analysis of that endpoint with an effect estimate or uncertainty interval. It also does not provide the planned pharmacokinetic and pharmacodynamic results in the information. As a result, the record does not support a comprehensive evaluation of the study's stated objectives.

The counts should not be generalized uncritically beyond this study. Participants were healthy subjects, not a population described as having systemic lupus erythematosus, despite lupus appearing in the condition field. The study involved single doses and small listed safety groups; it does not describe repeated treatment or clinical outcomes in people with lupus. The registry record also does not report long-term follow-up beyond the primary endpoint timeframe.

Statistically, the main lesson is the distinction between an observed count and an estimate of a broader treatment effect. Counts can be informative for describing the recorded safety experience, but uncertainty, comparative inference, and causal attribution require additional analysis and context. Those are not reported in the registry record. The data therefore should not be interpreted as proving either the presence or absence of a clinically meaningful treatment effect.

13. Why This Trial Matters Statistically

This study is statistically notable because it is a first-in-human investigation with multiple listed dose levels and a placebo group, while its stated purpose is to gather initial safety, tolerability, pharmacokinetic, and pharmacodynamic information. In such settings, descriptive data are important: they document observed events and can inform later research planning. The counts are not equivalent to definitive comparative evidence.

The record also illustrates why design labels and arm descriptions need to be read together. It labels the model as single-group but lists multiple AMG 570 dose groups and placebo. Since no explanation is recorded, the discrepancy should remain visible rather than being resolved by assumption. Likewise, randomization and quadruple masking are reported, but procedural details are not.

Small participant counts make uncertainty central to interpretation. A count of zero serious events in a group does not establish zero underlying risk, and observed differences between groups do not alone demonstrate a dose-related pattern. Confidence intervals and an analysis plan would help characterize uncertainty and intended comparisons, but they are not reported in the registry record.

Finally, the outcome reporting is limited: the record lists 13 outcome measures and 0 analyses, without a posted primary endpoint analysis. This makes clear the distinction between registering an outcome and reporting its statistical results. Readers can describe the adverse-event counts, but cannot assess formal treatment comparisons, multiplicity handling, or the precision of the primary result from this record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not provide a complete statistical analysis plan, sample-size justification, or formal analysis of the primary endpoint. It does not report confidence intervals, p-values, adjusted estimates, or a defined method for comparing dose groups with placebo. Consequently, the posted counts cannot support a formal inference about group differences.

The trial is described as randomized and quadruple-masked, but the record does not report the randomization procedure, allocation concealment, masking roles, or the specific assignment process across the listed dose groups. The model is labeled single-group even though multiple dose groups and placebo are listed; the registry does not explain this mismatch.

The participants are described as healthy subjects, while systemic lupus erythematosus is listed in the condition field. The record does not explain that field's relationship to the enrolled population. Results in healthy subjects should not be treated as direct evidence about participants with lupus.

The posted safety summaries do not include detailed event narratives, timing, duration, outcomes, or exposure-adjusted measures. The registry record does not explain missing-data handling, completeness of follow-up, protocol deviations, or how participants with incomplete assessments contributed to outcomes. It also does not report the numerical results for the listed pharmacokinetic and pharmacodynamic outcomes. These gaps constrain both the descriptive safety interpretation and assessment of the study's broader objectives.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Single Ascending Dose Study of AMG 570 in Healthy Subjects — NCT02618967.
• Registry record last updated 2024-05-14; status last verified 2024-05.
• Results first posted 2021-10-15.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes NCT02618967, a completed Phase 1, randomized, double-blind, placebo-controlled, first-in-human study of single subcutaneous doses of AMG 570 in healthy subjects. Enrollment was 56. Listed dose groups were 7 mg, 21 mg, 70 mg, 140 mg, 210 mg, 420 mg, and 700 mg, alongside matching placebo. The study's stated aims included safety, tolerability, pharmacokinetics, and pharmacodynamics.

The primary endpoint was the number of participants with one or more treatment-emergent adverse events from Day 1 to Day 105. The posted safety data report serious and other adverse-event counts by group and list no deaths. The registry record lists 13 outcome measures and 0 analyses, and does not report a primary endpoint analysis, uncertainty estimates, statistical plan, sample-size justification, or missing-data procedures. The counts are descriptive and do not establish causal or comparative effects.